In Silico identification and modelling of FDA-approved drugs targeting T-type calcium channels.
Studies have shown that inhibition of the Cav3.1 T-type calcium channel can prevent or suppress neurological diseases, such as epileptic seizures and diabetic neuropathy. In this study, we aimed to use in silico simulations to identify a U.S. Food and Drug Administration (FDA)-approved drug that can...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Public Library of Science (PLoS)
2025-01-01
|
| Col·lecció: | PLoS ONE |
| Accés en línia: | https://doi.org/10.1371/journal.pone.0327386 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|